Investigating new treatments for tuberculosis and related infections
Official title: Studies of lipoamide dehydrogenase tight binding inhibition in tuberculous and non-tuberculous mycobacteria
Funded at Weill Medical Coll of Cornell Univ · NIH-10991405 · Data updated 2026-11-12
This study is looking for new antibiotics that can help fight tuberculosis and similar infections by targeting a specific enzyme that the bacteria need to survive, which could lead to better treatments for patients, especially as some current medicines are becoming less effective.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | November 22, 2023 |
| Project end | October 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $576,414 |
| NIH project number | 5R01AI175342-02 |
| Project ID | NIH-10991405 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with tuberculosis or non-tuberculous mycobacterial infections, especially those who have not responded well to current treatments.
✕Less likely to help
Patients with infections caused by bacteria other than mycobacteria may not benefit from this research.
What this research studies
This research focuses on developing new antibiotics targeting lipoamide dehydrogenase, an enzyme crucial for the survival of tuberculosis (TB) bacteria. By exploring this previously unexamined target, the study aims to create effective treatments that can combat both TB and non-tuberculous mycobacterial infections. The approach involves testing various compounds to identify those that can inhibit this enzyme, potentially leading to new therapeutic options for patients. The research is particularly relevant given the rising resistance to existing TB treatments.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective and less toxic treatments for tuberculosis and related infections.
How similar studies have gone: While there have been successful studies targeting other aspects of TB treatment, this specific approach targeting lipoamide dehydrogenase is novel and has not been extensively tested.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Bryk, Ruslana — Weill Medical Coll of Cornell Univ
- Study coordinator: Bryk, Ruslana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.